Immunome (NASDAQ:IMNM) Insider Sells $27,300.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) insider Kinney Horn sold 1,092 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $25.00, for a total value of $27,300.00. Following the completion of the sale, the insider directly owned 1,092 shares in the company, valued at approximately $27,300. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunome Stock Performance

Shares of NASDAQ:IMNM traded down $0.82 during midday trading on Friday, reaching $23.35. 1,104,893 shares of the company’s stock traded hands, compared to its average volume of 1,759,821. The company has a fifty day simple moving average of $21.02 and a two-hundred day simple moving average of $21.88. Immunome, Inc. has a 1 year low of $7.96 and a 1 year high of $27.65. The company has a market cap of $2.64 billion, a P/E ratio of -9.81 and a beta of 2.07.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.12. As a group, research analysts forecast that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

Institutional Trading of Immunome

Hedge funds and other institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Immunome by 44.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company’s stock valued at $316,000 after acquiring an additional 14,398 shares during the last quarter. Creative Planning purchased a new position in Immunome during the second quarter worth about $167,000. Rhumbline Advisers raised its stake in Immunome by 22.0% during the second quarter. Rhumbline Advisers now owns 108,414 shares of the company’s stock worth $1,008,000 after purchasing an additional 19,526 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Immunome by 3.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 280,816 shares of the company’s stock valued at $2,612,000 after purchasing an additional 9,686 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of Immunome in the 2nd quarter valued at approximately $1,021,000. 44.58% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating on shares of Immunome in a research report on Thursday. Wedbush reiterated an “outperform” rating and set a $31.00 price objective on shares of Immunome in a research note on Friday, June 12th. Barclays began coverage on Immunome in a report on Thursday, May 28th. They set an “overweight” rating and a $36.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Finally, Wall Street Zen lowered Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Thirteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $33.17.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.